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Abstract Enteropathogenic Escherichia coli (EPEC) trig-
gers a large release of adenosine triphosphate (ATP) from
host intestinal cells and the extracellular ATP is broken
down to adenosine diphosphate (ADP), AMP, and adeno-
sine. Adenosine is a potent secretagogue in the small and
large intestine. We suspected that ecto-5′-nucleotidase
(CD73, an intestinal enzyme) was a critical enzyme
involved in the conversion of AMP to adenosine and in
the pathogenesis of EPEC diarrhea. We developed a
nonradioactive method for measuring ecto-5′-nucleotidase
in cultured T84 cell monolayers based on the detection of
phosphate release from 5′-AMP. EPEC infection triggered a
release of ecto-5′-nucleotidase from the cell surface into the
supernatant medium. EPEC-induced 5′-nucleotidase release
was not correlated with host cell death but instead with
activation of phosphatidylinositol-specific phospholipase C
(PI-PLC). Ecto-5′-nucleotidase was susceptible to inhibition
by zinc acetate and by α,β-methylene-adenosine diphos-
phate (α,β-methylene-ADP). In the Ussing chamber, these
inhibitors could reverse the chloride secretory responses
triggered by 5′-AMP. In addition, α,β-methylene-ADP and
zinc blocked the ability of 5′-AMP to stimulate EPEC
growth under nutrient-limited conditions in vitro. Ecto-5′-
nucleotidase appears to be the major enzyme responsible
for generation of adenosine from adenine nucleotides in the
T84 cell line, and inhibitors of ecto-5′-nucleotidase, such as
α,β-methylene-ADP and zinc, might be useful for treat-
ment of the watery diarrhea produced by EPEC infection.
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Abbreviations
α,β-methylene-
ADP
α,β-methylene-adenosine diphosphate, an
ecto-5′-nucleotidase inhibitor; also called
AMP-CP and APCP by other investigators
EPEC enteropathogenic Escherichia coli
PMN polymorphonuclear neutrophil
PI-PLC phosphatidylinositol-specific
phospholipase C
U73122 a PI-PLC inhibitor; see “Materials and
methods” for full chemical name
Introduction
Ecto-5′-nucleotidase (CD73,EC3.1.3.5)isa keyextracellular
enzyme which catalyzes the hydrolysis of extracellular
nucleoside monophosphates to their corresponding nucleo-
sides, with 5′-AMP being the preferred substrate. Ecto-5′-
nucleotidase is highly expressed in endothelium, liver, and
intestinal mucosa and at varying levels in other tissues
including lymphocytes, kidney, and certain cancers. Ecto-5′-
nucleotidase is tethered to the extracellular surface of
mammalian cells by a glycosylphosphatidylinositol (GPI)
lipid anchor. Most of the research on this enzyme has been in
the cardiovascularsystembecause ofits roleinthe production
of adenosine, which protects cells against ischemia by
multiple mechanisms including vasodilation [1, 2].
Enteropathogenic Escherichia coli (EPEC) is a common
cause of watery diarrhea in children in developing
countries. While some aspects of EPEC infection, such as
adherence, are well studied, the way that EPEC triggers
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toxins. We recently proposed a theory that release of
adenine nucleotides from host intestinal cells, followed by
breakdown to adenosine, could trigger watery diarrhea by
activation of adenosine receptors on intestinal cells [3].
In the gastrointestinal tract, ecto-5′-nucleotidase was
found to be a key enzyme necessary for enterocyte
responses to 5′-AMP, the neutrophil-derived secretagogue
[4–6]. At that time the significance of ecto-5′-nucleotidase
was felt to be in the setting of invasive, inflammatory
pathogens because polymorphonuclear neutrophils (PMNs)
release 5′-AMP during the process of chemotaxis into areas
of infection or inflammation. Since that time, however, we
have discovered that a noninvasive pathogen, EPEC,
triggers a large release of ATP directly from host intestinal
cells without any requirement for PMNs to be present [3].
Other diarrheal pathogens not considered classically inva-
sive, such as Aeromonas hydrophila, also cause ATP
release from enterocytes [7]. Extracellular ATP is broken
down to ADP, AMP, and then adenosine, where it triggers a
vigorous fluid secretory response in intestinal epithelium.
We suspected that ecto-5′-nucleotidase also played a role in
the diarrheal fluid secretion induced by EPEC and initiated
this study to determine if it is the case, and, if so, whether
inhibitors of ecto-5′-nucleotidase could block fluid secre-
tion triggered by adenine nucleotides and EPEC infection.
We used the T84 colon carcinoma cell line as a model
because we have used these cells to study EPEC infection,
they express ecto-5′-nucleotidase, and they can be studied
in the Ussing chamber to measure chloride secretion. In
order to facilitate our study we also developed a nonradio-
active, non-high-pressure liquid chromatography (non-
HPLC) method for measuring ecto-5′-nucleotidase in living
T84 cell monolayers.
Materials and methods
Bacterial strains used E. coli strains used included labora-
tory E. coli strain HB101 (O: rough), commensal strain HS
(O9: H4), and classic human EPEC strains E2348/69
(serotype O127: H6), B171-8 (O111: NM), and JCP88
(O119: B14) as described in several publications [8–12].
EPEC mutants included JPN15, an E2348 derivative which
has lost the EPEC adherence factor (EAF) plasmid [13],
UMD874, the espF mutant derived from E2348, which is
deficient in host cell killing [3, 14], and SE1010, with a
mutation in sepZ (also called espZ), which is defective in
type III secretion [15]. Bacteria were added to yield a
multiplicity of infection (MOI) of 100:1.
Materials The following reagents were obtained from
Sigma-Aldrich Chemicals: α,β-methylene-ADP, adenosine,
adenosine 5′-monophosphate (AMP), tetramisole (also
called levamisole), polymyxin B, neomycin, purified
phosphatidylinositol-specific phospholipase C (PI-PLC,
from Bacillus cereus), and zinc acetate. BIOMOL (Ply-
mouth Meeting, PA, USA) was the source of the BIOMOL
GREEN reagent used in the phosphate release assay for
nucleotidase activity and of U73122, a PI-PLC inhibitor.
U73122 is 1-(6-[17 beta-3-methoxyestra-1,3,5- (10) triene-
17-yl] amino/hexyl) 1H-pyrroledione. A cell permeant PI-
PLC activator, 3M3-FBS, was from the Calbiochem
Division of EMD Biosciences (La Jolla, CA, USA). 3M3-
FBS is 2,4,6-trimethyl-N-(m-3-trifluoromethylphenyl)ben-
zenesulfonamide. Phosphate-free DMEM medium was
purchased from MP Biomedicals (formerly ICN Biomed-
icals, Aurora, OH, USA). UNIFILTER plates were from
Whatman (Clifton, NJ, USA).
Bacterial culture E. coli strains were grown overnight in
Luria-Bertani (LB) broth at 37°C with 300 rpm shaking,
then subcultured for 2 h in serum-free DMEM/F12 medium
supplemented with 18 mM NaHCO3, 25 mM hydroxye-
thylpiperazine ethanesulfonic acid (HEPES) buffer, pH 7.4,
and 1% D-mannose as previously described [3]. For
experiments with bacteria in minimal medium, bacteria
were subcultured at a dilution of 1:2,000 into minimal
medium (M9 salts plus casamino acids supplemented with
2 mM glucose). For convenience we used M9-CA liquid
broth packets (E. coli Fast Media, MBI-Fermentas, Hano-
ver, MD, USA) and added 2 mM glucose before use.
Cell culture T84 colon cancer cells were grown in DMEM/
F12 medium supplemented with 7.5% fetal bovine serum
(Gibco/Invitrogen, Grand Island, NY, USA), 18 mM
NaHCO3,2 0μg/ml vancomycin, and 15 μg/ml gentamicin
as previously described [16]. Ussing chamber studies of
secretion were performed on T84 cell monolayers grown in
Snapwell inserts (Corning Costar, Corning, NY, USA). The
Snapwell inserts, which had a 0.4 μm pore size, were
coated with 32 μg collagen per well by applying 0.16 ml of
0.2 mg/ml type III collagen (Sigma; dissolved in warm
0.2 M acetic acid) to the Snapwell and allowing it to dry in
the tissue culture hood under UV light. T84 cells were
seeded onto the Snapwell inserts at ~1.2×10
6 cells per well
and allowed to grow to confluency for 7–9 days. At this
time the monolayers had transepithelial electrical resistan-
ces (TER) of 400–1,000 Ω ·c m
2.
Assay for ecto-5′-nucleotidase by phosphate release An
assay for ecto-5′-nucleotidase activity in living cells was
developed based on the ability to detect inorganic phos-
phate (Pi) released from 5′-AMP. This method has been
used to detect activity of protein phosphatases such as
PTEN [17] and lipid phosphatases [18] and is based on
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GREEN reagent, an enhanced and stabilized formulation of
malachite green. To carry out the assay a phosphate-free
buffer was used consisting of (in mM): NaCl, 154; KCl, 2:
MgCl2, 4; NaHCO3, 18: HEPES, pH 7.4, 25; and glucose,
10. This buffer is referred to as nucleotidase buffer. To
measure ecto-5′-nucleotidase activity, the cell monolayer
was rinsed once with sterile normal saline, then the medium
was replaced with warm nucleotidase buffer. For cells in a
48-well plate, 0.25 ml of nucleotidase buffer were added
per well, and the cells were allowed to rewarm to 37°C in
the CO2 incubator. During pipetting the multiwell plate was
kept warm using a metal heating block set at 37°, and a
stopwatch was used to time the AMP addition and to
terminate the assay. The procedure used for measuring
monolayer activity was slightly different from that used to
measure 5′-nucleotidase activity released into the superna-
tant, as described below.
Cell-bound or monolayer activity To measure cell-bound
ecto-5′-nucleotidase activity in cell monolayers, 5′-AMP
was added to yield a final concentration of 0.2 mM to
quadruplicate wells. Two other wells were left without
addition of AMP (the “no AMP blank”). After a 10-min
incubation at 37° an aliquot (usually 50 μl) was removed
and quickly transferred to a well of a 96-well plate to
terminate the reaction.
E. coli-induced release of nucleotidase activity into the
supernatant medium For nucleotidase release experi-
ments, the cell monolayer was changed to warm,
phosphate-free DMEM, then infected with an E. coli
strain for 35 min to allow adherence, then the medium was
changed to nucleotidase buffer and the infection was
allowed to continue for 2 or 3 h. Note that in this
procedure any nucleotidase activity that is released in the
first 35 min is discarded and not detected by our method.
However, this two-stage procedure with the medium
change was necessary because EPEC bacteria did not
adhere normally if they first encountered the host cell in
nucleotidase buffer. After a period of infection, supernatant
medium was collected with a multichannel pipettor and
transferred to the wells of a Whatman UNIFILTER plate (a
96-well with 0.45-μm membrane for sterile filtration).
Sterile filtrates were prepared by centrifugation with
collection of the filtered medium into another 96-well
plate placed beneath the UNIFILTER as previously
described [19]. Once again, experimental conditions were
usually done in groups of six, with two wells not receiving
any AMP (no AMP blanks) and four wells receiving
0.2 mM AMP. Again, the usual assay condition was
10 min at 37° before the reaction was stopped by addition
of 10 μl of 1 M HCl (“stop solution”).
BIOMOL GREEN detection of phosphate released from
AMP Stopped samples in a 96-well plate were brought to
100 or 110 μl volume with water if necessary, then treated
with 100 μl of BIOMOL GREEN reagent. A standard
curve of inorganic phosphate was prepared and run with
every experiment; standards and unknown samples were
incubated at room temperature for 20 min to allow a green
color to develop, then the 96-well plate was read on a
multiwell plate spectrophotometer at 620 nm. Unknown
values were calculated from the standard curve using a
hyperbolic curve fit using GraphPad Prism software,
version 4.0. Results of monolayer activity were expressed
as nmol of Pi produced/min per 10
6 cells. For experiments
showing nucleotidase release, the results were often
expressed as nmol Pi released/ min per well since the assay
was done on a cell-free filtrate and because we often noted
some detachment of cells during the longer incubations of
2–3 h needed to observe release.
Although we believed we were developing a new
method for assay of ecto-5′-nucleotidase by phosphate
release, during the course of this work another group
reported using a virtually identical method, also based on
detection of phosphate released from 5′-AMP [1].
Detection of CD73 by Western immunoblot To prove that
the released 5′-nucleotidase activity we measured was of
host cell rather than bacterial origin, we performed
immunoblots on the supernatants of infected T84 cells with
antibodies against CD73. Initial attempts at immunoblotting
using a commercially available monoclonal anti-CD73
antibody (Abnova Corp., Taipei, Taiwan) were unsuccess-
ful. Dr. Linda F. Thompson, Oklahoma Medical Research
Foundation, kindly sent us mouse monoclonal antibodies
against human CD73 which had been generated by Dr.
Wolf Gutensohn several years earlier. Of these, the two
antibodies that gave the best results were designated
CD73.4 and CD73.6 by Dr. Gutensohn; both were of
isotype IgG2b and were used at a concentration of 1 μg/ml.
After washings, the secondary antibody was goat anti-
mouse IgG2b conjugated to peroxidase at a dilution of
1:3,000 (Roche Molecular Biochemicals, Indianapolis, IN,
USA). Blots were developed by chemiluminescence as
previously described [20].
Ussing chamber studies A Snapwell insert containing a
monolayer of T84 cells was placed in the plexiglass “slider”
and inserted into the Ussing chamber (Physiologic Instru-
ments, San Diego, CA, USA) at 37°C and continuously
short-circuited by a four electrode, automatic voltage-clamp
apparatus which measured short-circuit current (Isc) and
transepithelial resistance (TER); chamber fluid resistance
was automatically subtracted. Transepithelial resistance was
determined by passing 10-s 10-mV current pulses through
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sufficient current through the tissues via Ag/AgCl electro-
des to reduce the spontaneous transepithelial potential to
zero. The composition of the tissue bathing solution was (in
mM): 140 Na
+, 124 Cl
−, 21 HCO3-, 5.4 K
+,2 :4 HPO2
4;
0:6H 2PO
4 ,1.2Mg
2+, 1.2 Ca
2+, and 10 glucose. Raw short-
circuit current (Isc) values were converted to μA per cm
2
by dividing by the area of the Snapwell monolayer
(1.13 cm
2). Other details of the Ussing chamber methods
were exactly as described [16].
Protein assay Protein assay was by the Coomassie blue
dye binding assay method of Bradford, using a Bio-Rad
kit [21].
Expression of ecto-5′-nucleotidase RNA by reverse tran-
scription and real-time polymerase chain reaction (PCR)
T84 cells grown in 24-well plates were infected with EPEC
for 35 min, then the medium was changed to remove
unbound bacteria. Three hours after the medium change,
ciprofloxacin was added to 25 μg/ml to kill EPEC and the
incubation was continued 1 more hour. Old medium was
removed, and the cell monolayer was lysed in extraction
buffer with 10% β-mercaptoethanol (RNeasy Kits, Qiagen,
Valencia, CA, USA). RNA was subjected to reverse
transcription using Invitrogen Superscript III reverse tran-
scriptase; 5 μl of purified RNAwas used per 50 μl reaction,
and gene-specific primers at 0.2 μM were used. Reverse
transcription reaction was at 55° for 1 h. Copy DNA from
reverse transcription was diluted 100-fold, then analyzed by
quantitative real-time PCR using the same oligonucleotide
primers. For ecto-5′-nucleotidase the primers used were 5′-
TTC CAC CCT GAA GAA GGC CTT TGA-3′ (forward)
and 5′-ATA ACT GGG CAC TCG ACA CTT GGT-3′
(reverse). As a normalizing gene we used glyceraldehyde
phosphate dehydrogenase (GAPDH) as described by Khan
et al. [22] except that we redesigned longer primers which
were 5′-TCG ACA GTC AGC CGC ATC TTC TTT-3′ and
5′-ACC AAA TCC GTT GAC TCC GACC CTT-3′. PCR
was carried out using a MyiQ Single-Color qRT-PCR
machine from Bio-Rad (Hercules, CA, USA) using SYBR
Green as the dye to monitor the amplification. Relative
expression was calculated by the ΔΔCt (“Livak”) method
as described [23], where Ct is the number of cycles to
threshold. SYBR Green PCR reagents were from Bio-Rad
and to reduce the cost, the PCR reaction volume was
reduced to 25 μl. PCR was performed using a two-step
protocol with an annealing temperature of 58.7° and
denaturation at 95° for 30 s each (i.e, no extension step)
for 35 cycles. Thermal melt curve analysis was performed
at the end of the PCR amplification and showed a single
sharp peak for the genes analyzed.
Data analysis and presentation All error bars shown in
graphs and error values reported in the text are standard
deviations. Significance was tested by one-way analysis of
variance (ANOVA) with the Tukey-Kramer post-test for
multiplecomparisons,usingInStatsoftwarefortheMacintosh
fromGraphPadsoftware(SanDiego,CA,USA).Graphswere
prepared using Prism 4.0 software, also from GraphPad.
Asterisks shown on graphs indicate a p value of <0.05.
Results
Ecto-5′-nucleotidase activity was readily measurable in T84
cell monolayers using the phosphate release assay method
developed in this study. Figure 1 shows the characteristics
of the ectoenzyme in this system. Figure 1a shows a curve
of activity vs substrate concentration, demonstrating that
the enzyme shows Michaelis-Menten kinetics. In four
experiments similar to that shown in Fig. 1a, the KM was
229±30 μM and the Vmax was 2.7±1.8 nmol/min per 10
6
cells (mean ± SD of 4 experiments). While the KM was
very consistent over time and from experiment to experi-
ment, the Vmax was more variable as we compared
experiments separated by months or years. We noted that
highly T84 passaged cells (passage number of 70 or
greater) showed lower levels of ecto-5′-nucleotidase activ-
ity than less passaged cells from the same source (experi-
ments not shown). The KM we observed in intact T84 cells
was higher than that reported for the purified enzyme
derived from a colon carcinoma cell line, BCS-TC2 cells
[24]. Figure 1b shows the raw data of Pi generated over
time in the presence and absence of added AMP substrate
and demonstrates that the assay was linear for 10 min; there-
fore, 10 min was chosen as the standard assay duration.
Alkaline phosphatase is another abundant intestinal
ectoenzyme which can hydrolyze 5′-AMP [25]. Alkaline
phosphatase can be distinguished from 5′-nucleotidase by
its alkaline pH optimum and sensitivity to inhibition by
tetramisole. Figure 1c shows that the ectonucleotidase we
measured on T84 cells was not inhibited by tetramisole
(also known as levamisole). Furthermore, its activity did
not increase with increasing pH (Fig. 1d) providing
evidence that the activity being measured was not alkaline
phosphatase. In addition, we used HPLC to confirm that 5′-
AMP was being converted to adenosine in the supernatant
medium of T84 cells (Fig. 1e and f). Morover, the 5′-
nucleotidase activity we measured by phosphate release
was sensitive to inhibition by α,β-methylene-ADP, a
known inhibitor of ecto-5′-nucleotidase (Fig. 1g and see
also Fig. 4). Lastly, after we initiated this study, other
researchers also reported using phosphate release from
5′-AMP as their assay for ecto-5′-nucleotidase [1]. We have
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release assay increases its usefulness compared to the much
slower HPLC methods for ecto-5′-nucleotidase.
Figure 2 shows the effect of EPEC infection on ecto-5′-
nucleotidase activity released into the supernatant medium
during an experimental EPEC infection of cultured T84
cells. Wild-type EPEC strains E2348/69 and JCP88
triggered a release of 5′-nucleotidase into the supernatant
medium while nonpathogenic E. coli strains HB101 and HS
did not. The supernatant medium was subjected to sterile
filtration prior to assay to remove bacterial cells as well as
any detached host cells, so that the activity reflects a
soluble and not a cell-bound form. In experiments where
we determined both the supernatant release and the
monolayer activity in the same experiment, supernatant
release by wild-type EPEC was 30–40% of monolayer
activity 3 h after the medium change (Fig. 2a and data not
shown). To determine if the 5′-nucleotidase could possibly
be derived from the E. coli bacteria rather than from the
host we also assayed sterile filtrates of E. coli for 5′-
nucleotidase activity and it was virtually absent from the
culture filtrates of all E. coli strains tested, including EPEC
(Fig. 2b, light gray bars). Even after treatment with a
concentration of polymyxin B sufficient to cause >99%
bacterial cell lysis the amount of bacterial nucleotidase-like
activity was far less than the amounts we observed in the
Fig. 1 Characterization of ecto-
5′-nucleotidase activity in T84
cell monolayers. 5′-Nucleotidase
activity was measured by the
release of inorganic phosphate
(Pi) from AMP in phosphate-
free buffer using a colorimetric
method as described in “Materi-
als and methods.” For a, c, and
d, the spectrophotometric read-
ing in the absence of AMP (“no
AMP blank”) was subtracted
from the total reading. In b the
“no AMP blank” was not sub-
tracted and is shown in b as
labeled. a Michaelis-Menten
curve of enzyme velocity vs
concentration of AMP substrate.
b Time course of Pi release vs
time. c Lack of inhibition by
tetramisole, an inhibitor of alka-
line phosphatase. d pH depen-
dence of 5′-nucleotidase activity.
e, f HPLC traces showing con-
version of AMP (e) to adenosine
(Ado, f) in T84 cell monolayers.
g Sensitivity of the AMP-hydro-
lyzing activity to the inhibitor
α,β-methylene-ADP, confirm-
ing it as ecto-5′-nucleotidase
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medium change step in order to remove unbound bacteria.
Therefore we concluded that the 5′-nucleotidase activity
being released in Fig. 2a was of host cell origin.
To determine if this hypothesis was correct and to try to
determine the mechanism of EPEC-induced 5′-nucleotidase
release, we compared the 5′-nucleotidase release triggered by
wild-type EPEC strain E2348/69 with the plasmid-cured
derivative, JPN15, and its espF mutant, UMD874 (Fig. 3a).
The espF mutant is defective in host cell killing and in
inducing damage to monolayer integrity [14, 26]. Interest-
ingly, the espF mutant was not attenuated in its ability to
trigger 5′-nucleotidase release, but instead it consistently
outperformed the wild-type strain in this regard. In six
experiments 5′-nucleotidase release induced by the espF
mutant exceeded that of the wild-type E2348/69 by an
average of 2.3±0.14 fold (p= 0 . 0 3b yp a i r e dt-test), suggest-
ing that host cell death or damage is not the mechanism of
EPEC-induced nucleotidase release.
Ecto-5′-nucleotidase is tethered to the extracellular
surface of the cell by a glycosylphosphatidylinositol (GPI)
lipid anchor [24, 27]. GPI lipid anchors are cleaved by
phosphatidylinositol-specific phospholipases C (PI-PLC),
and EPEC has been shown to activate at least one type of
PI-PLC in the host cell, PI-PLC-γ [28]. Therefore we
considered whether PI-PLC activation by EPEC could be a
nonlethal mechanism by which EPEC triggered 5′-nucleo-
tidase release from host intestinal cells.
Figure 3b shows an experiment in which we tested
whether a PI-PLC inhibitor could block EPEC-induced
nucleotidase release. Indeed, 2 μM U73122 did reverse the
nucleotidase release triggered by wild-type EPEC strains.
Conversely, a newly described cell-permeable activator of PI-
PLC, called m-3M3-FBS [29], triggered nucleotidase release
from uninfected cells in a time- and concentration-dependent
manner (Fig. 3c). Experiments to test if m-3M3-FBS would
enhance EPEC-induced release were inconsistent, with some
experiments showing a mild enhancement or additive effect
and others showing no enhancement or mild antagonism
(results not shown).
In addition we also tested whether purified PI-PLC added
to the apical surface of the T84 cell monolayer induced 5′-
nucleotidase release and it did (Fig. 3d and e). Figure 3da l s o
shows that 50 μg/ml neomycin could partially block 5′-
nucleotidase release by purified PI-PLC. In addition to its
antimicrobial effects, neomycin is an inhibitor of several
types of PLC enzymes including PI-PLC. Figure 3es h o w s
that after a 2-h treatment with PI-PLC not only was 5′-
nucleotidase activity increased in the supernatant, but that
monolayer activity was depleted as well (right portion of
Fig. 3e). In experiments similar to Fig. 3ed o n ew i t hE P E C
infection, we could not detect any decrease in monolayer
activity 2–3 h after infection, despite the liberation of 5′-
nucleotidase activity into the supernatant. We considered the
possibility that increased host cell synthesis of ecto-5′-
nucleotidase might be occurring in response to the cleavage
of the enzyme from the cell surface. We analyzed the
abundance of RNA encoding ecto-5′-nucleotidase by reverse
transcription and real-time quantitative PCR in response to
EPEC infection. Figure 3f and Table 1 show that infection
with wild-type EPEC and the EPEC espF mutant (UMD874)
increased the abundance of ecto-5′-nucleotidase RNA
compared to uninfected control cells. The increase in
expression of ecto-5′-nucleotidase RNA by wild-type EPEC
was 33% above control. While this is not a large increase, it
does explain the maintenance of normal levels of ecto-5′-
nucleotidase on the surface of EPEC-infected cells, because
under the most optimum conditions the release of enzyme
activity into the supernatant is about 30–40% of monolayer
activity (e.g., Fig. 3e).
Fig. 2 Effect of E. coli infection on 5′-nucleotidase activity in the
supernatant medium. a Nonpathogenic E. coli strains (HB101 and HS)
or EPEC strains E2348/69 and JCP88 were subcultured in DMEM
medium for 2 h, then used to infect T84 cells at a multiplicity of
infection of 100:1 in phosphate-free DMEM. After 35 min to allow
adherence, the medium was changed to nucleotidase buffer and
aliquots were collected at various times after the medium change,
filtered through a 0.45-μm filter to remove bacterial cells, then
assayed for 5′-nucleotidase activity. Since the activity was measured in
the cell-free sterile filtrates the activity is expressed as nmol/min per
well. b E. coli suspensions were subjected to sterile filtration without
treatment (light gray bars) or following treatment with 50 μg/ml
polymyxin B, a lytic antibiotic (dark gray bars). Then the nucleotid-
ase activity of a 100-μl aliquot was measured. The 100 μl volume was
chosen because this was the volume of inoculum needed to achieve an
MOI of 100:1 for the slowest growing strain (E2348/69) in a typical
48-well plate of T84 cells
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on induced 5′-nucleotidase release into supernatant. Release of 5′-
nucleotidaseactivityintosupernatantmediumwasmeasuredasdescribed
in “Materials and methods” and in the legend to Fig. 2.O n c ea g a i n ,
activity in the cell-free sterile filtrates is expressed as nmol/min per well.
However, for purposes of comparison 48-well plates contain ~0.25×10
6
T84 cells per well at confluency. b U73122, an inhibitor of PI-PLC, was
used at a concentration of 2 μm and was re-added after the medium
change; *significantly decreased compared to the EPEC strain alone,
p<0.05.c m-3M3-FBS, a cell-permeant sulfonamide activator of PI-PLC,
was added at the concentrations and for the times indicated. d Inhibitory
effect of neomycin on PI-PLC-induced 5′-nucleotidase release; this
experiment was performed on cells grown in a 24-well plate, with
~0.8×10
6 cells per well; *significantly decreased compared to PI-PLC
alone. e PI-PLC was again added to a final concentration of 0.1 U/ml
for the times shown; *significantly different from the corresponding
control. This figure is a composite of experiments that were separated in
time and with cells of different passage number; therefore the absolute
amount of activity varies among the figure parts. f Effect of EPEC
infection on expression of RNA encoding ecto-5′-nucleotidase in T84
cells, by reverse transcription and real-time PCR. T84 cells were
infected for 35 min, then the supernatant medium was changed to
remove unattached bacteria, then the T84 cell monolayer harvested for
RNA extraction 4 h after the medium change. Reverse transcription and
PCR conditions were as described in “Materials and methods.”
Expression of ecto-5′-nucleotidase was normalized to that of glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH). f Normalized expres-
sion of a single representative experiment (mean ± SD of 6 PCR wells).
g Immunoblot analysis of the proteins released into the supernatant after
2 h of infection with EPEC or an EPEC mutant (SE1010, sepZ/espZ),
using monoclonal antibody against CD73. Lane 1, supernatant from
uninfected, control T84 cells. Lanes 2 and 3, supernatant from cells
infected with wild-type E2348/69. Lanes 4 and 5,s u p e r n a t a n t sf r o m
cells infected with the sepZ mutant. GPI-linked CD73 has an apparent
molecular size of 72 kDa (not seen in this blot) and the GPI-cleaved
soluble portion runs at 51 kDa (heavy band in lanes 2 and 3)
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appeared to be of host cell origin, because it could be
triggered by chemical stimuli in the absence of EPEC
infection (Fig. 3c–e). The host origin was also proven using
a mouse monoclonal antibody against human CD73. Wild-
type EPEC infection of T84 cells triggered the release into
the supernatant of a 51 kDa protein recognized by a mAb
against CD73 (Fig. 3g, lanes 2 and 3). In contrast, the
EPEC sepZ/espZ mutant, which is defective in type III
secretion, triggered the appearance of a fainter band which
was of ~55 kDa in size. The origin of this faint band is
unknown, but it is possible it is generated by proteolysis
rather than PI-PLC activation. For example, E2348/69
expresses EspC, an autotransporter protease whose export
is independent of type III secretion.
Figure 4 shows that 5′-nucleotidase activity in living T84
cells was susceptible to the same inhibitors as the purified
enzyme studied by others. Figure 4a shows that α,β-
methylene-ADP inhibited ecto-5′-nucleotidase activity and
that its inhibition has the characteristics of a competitive
inhibitor. In the presence of α,β-methylene-ADP the enzyme
shows an apparent increase in KM but no increase in the
Vmax, and the inhibition can be overcome at high concen-
trations of AMP substrate. In contrast in Fig. 4b one
observes that zinc acetate behaves as a noncompetitive
inhibitor of the enzyme, with a decrease in the Vmax but no
increase in the KM (in fact there is a small, paradoxical
decrease in KM in the presence of zinc). Figures 4ca n dd
show the inhibitory dose-response curves at a single 0.2 mM
concentration of AMP substrate. For both inhibitors, when
concentration is expressed on a logarithmic scale, the curves
Fig. 4 Effect of the 5′-nucleo-
tidase inhibitors on enzyme ac-
tivity in T84 cell monolayers.
a, b Michaelis-Menten curves of
enzyme activity vs substrate
concentration in the absence
(open symbols) and presence
(closed symbols) of the inhibitor
shown. Enzyme parameters
were calculated by nonlinear
curve fitting using GraphPad
Prism and the fitted parameters
of Vmax and KM are shown
below the graphs. c, d Dose-
response curves for inhibition of
ecto-5′-nucleotidase activity by
α,β-methylene-ADP (c) and
zinc acetate (d) using a 0.2 mM
concentration of AMP substrate.
In all parts of Fig. 4 the inhibitor
was added before the AMP, and
in c and d the curves were fitted
to a sigmoidal inhibitory dose-
response curve and the inhibito-
ry concentration 50% (IC50)
value derived from the curve fit
is shown
Table 1 Effect of EPEC infection on expression of RNA encoding
ecto-5′-nucleotidase in T84 cells, by reverse transcription and real-
time PCR
Condition Normalized expression ratio
a
Uninfected control 1.0, by definition
+1 U/ml PI-PLC 1.23±0.26
HS-infected
b 0.66±0.22
E2348/69-infected
b 1.33±0.21
c
UMD874 (espF)-infected
b 1.40±0.19
c
aCells were infected for 35 min, then the supernatant medium was
changed to remove unattached bacteria, then the T84 cell monolayer
harvested for RNA extraction 4 h after the medium change.
Expression of ecto-5′-nucleotidase was normalized to that of glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). Data shown are the
means ± SD of 5 similar experiments
bBacteria were added with the intent of achieving a multiplicity of
infection (MOI) of 100:1; actual MOIs in the 5 experiments ranged
from 71 to 144
cSignificantly increased compared to uninfected control by paired t-
test (p=0.04)
240 Purinergic Signalling (2007) 3:233–246Fig. 5 Effect of 5′-nucleotidase inhibitors on the chloride secretory
responsetoAMPinT84cellsintheUssingchamber.Short-circuitcurrent
(Isc) was measured in T84 cells grown in Snapwell inserts as described
in “Materials and methods”; in this cell line and electrode configuration,
ap o s i t i v eI sc (upward deflection on the graphs) represents chloride
secretion in the basolateral to apical direction. All of the additions of
agonists and inhibitors in these parts of the figure was on the apical
(mucosal) side of the monolayers only. a Reversal of AMP-induced
secretory response by theophylline, an adenosine receptor antagonist. b
Partial inhibition of AMP-induced secretion by 2 mM zinc acetate, with
restoration of the tracing to its previous trend by adenosine, demon-
strating that adenosine receptors are not blocked by zinc. c Substantial
reversal of Isc by α,β-methylene-ADP when a low concentration of
AMP (1 μM) is used as the stimulus. Note that adenosine fully restores
secretion to its previous level. d Lesser degree of reversal of Isc by α,β-
methylene-ADP when a higher concentration of AMP (20 μM) is used
as stimulus. e Summary of many experiments in which fixed
concentrations of zinc and α,β-methylene-ADP were tested for
inhibitory efficacy against varying concentrations of AMP as test
stimulus. In Fig. 5e the slope of the α,β-methylene-ADP curve was
−1.73±0.5 by linear regression (95% confidence limits of the slope
value −3.27 to −0.2, significantly different from zero, p<0.04). In
contrast the slope of the zinc curve was −0.04±0.23 and did not differ
significantly from zero
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determination of the inhibitory concentration 50% (IC50)a s
shown in Figs. 4c and d. In addition to α,β-methylene-ADP
and zinc acetate, ecto-5′-nucleotidase activity was also
inhibited by 3–10 mM sodium fluoride as reported for the
purified enzyme (data not shown). 5′-Nucleotidase activity
released into the supernatant was also sensitive to inhibition
by α,β-methylene-ADP and zinc acetate with similar
potencies (data not shown).
In Fig. 4 the inhibitor was always added to the cell
monolayer prior to the AMP substrate. Using the Ussing
chamber apparatus to measure chloride secretion, we
realized we could monitor the effects of inhibition of 5′-
nucleotidase activity dynamically and assess the ability of
inhibitors to reverse a secretory response already underway.
In preliminary experiments we found that to reverse an
ongoing secretory stimulus we had to add inhibitors at
concentrations considerably above their IC50 values. The
requirement for addition of inhibitors well above the IC50 is
due to the fact that adenosine is a very potent secretagogue
in intestinal tissues and a very high degree of inhibition of
ecto-5′-nucleotidase is needed to reduce the production of
adenosine below the secretory threshold.
Figure 5a shows that secretion triggered by 10 μMA M P
is reversed by theophylline, an adenosine receptor antago-
nist. Figure 5a emphasizes the fact that 5′-AMP has no
secretory ability unless it is converted into adenosine.
Adenosine then acts via apical adenosine A2b receptors to
trigger chloride secretion toward the apical side of the
monolayer. Figure 5b shows that chloride secretion triggered
by 1 μM AMP is partially antagonized by 2 mM zinc acetate
even when the inhibitor is added after secretion has started.
Addition of 1 μM adenosine restored the short-circuit current
(Isc) to its previous trend, showing that zinc does not block
adenosine receptors or “poison” the secretory machinery.
Under the same experimental conditions, 200 μM α,β-
methylene-ADP produced a much larger degree of reversal
of Isc than did zinc (Fig. 5c). As with zinc, α,β-methylene-
ADP did not prevent a subsequent, normal Isc response to
addition of adenosine (Fig. 5c, right-hand portion), showing
that it is acting as a 5′-nucleotidase inhibitor and not an
adenosine antagonist. The efficacy of inhibition by α,β-
methylene-ADP in this paradigm, however, was strongly
RFig. 6 Effect of 5′-nucleotidase inhibitors on growth of EPEC strain
E2348/69 in minimal medium supplemented with 30 μM adenosine or
AMP. Minimal medium here refers to M9 salts, 2% casamino acids,
and 2 mM glucose. Growth was at 37°C with 300 rpm shaking after a
1: 2,000 dilution from an overnight culture in LB medium. a, c
Culture turbidity by spectrophotometric absorbance at 600 nm. b
Bacterial protein content. a, b Growth-enhancing effects of AMP are
blocked by α,β-methylene-ADP. c Growth-enhancing effects of AMP
are blocked by zinc acetate; *significantly decreased compared to
AMP alone (p<0.05)
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secretion. At higher concentrations of AMP (e.g., 20 μM),
the degree of inhibition by α,β-methylene-ADP was
markedly less (Fig. 5d) than when 1 μM AMP was used
as the stimulus. In contrast, zinc acetate produced the same,
modest inhibition of Isc regardless of the concentration of
AMP used. Figure 5e summarizes the effectiveness of the
two inhibitors, zinc and α,β-methylene-ADP, when tested
against various different concentrations of AMP as the initial
stimulus. Figure 5e shows that the effectiveness of α,β-
methylene-ADP declines significantly with increasing con-
centrations of AMP used, whereas zinc’s inhibitory effects
are fairly constant over a range of AMP concentrations. The
results of Fig. 5 (b–e) vividly illustrate, at the level of of an
electrophysiologic response, the difference between a com-
petitive and a noncompetitive mode of action of an enzyme
inhibitor (compare with Fig. 4a and b).
Since the discovery of EPEC-induced ATP release we
have hypothesized that EPEC bacteria may gain a nutri-
tional advantage by this inflicting kind of damage on the
host cell [3]. The lumen of the gastrointestinal tract is a
purine-limited environment, as demonstrated by in vivo
gene expression screens such as in vivo expression
technology (IVET) [30] and signature-tagged mutagenesis
(STM) [31]. Nucleotides and nucleosides enhance growth
of EPEC strains in vitro, and these growth-promoting
effects are most obvious when adenosine is added to
minimal medium (Fig. 6). Compared to minimal medium,
addition of 30 μM adenosine markedly accelerated growth
of EPEC strains such as E2348/69 (Fig. 6). Addition of 5′-
AMP also increased EPEC growth, although not as much as
adenosine. Alpha-β-methylene-ADP alone has no effect,
stimulatory or inhibitory, on EPEC growth, but it did
completely reverse the growth-promoting effects of 5′-AMP
(Fig. 6a and b, right-hand bars). Alpha-β-methylene-ADP
did not block the enhanced growth seen with adenosine (not
shown). Similarly, 100 μM zinc acetate did not affect
growth in minimal medium (Fig. 6c, left-hand bars) or the
enhanced growth seen with adenosine (Fig. 6c, two middle
bars), but zinc did abolish the enhancement of growth by
AMP. E. coli 5′-nucleotidase is susceptible to inhibition by
α,β-methylene-ADP and zinc; in fact, the crystal structure
of the E. coli enzyme was solved with α,β-methylene-ADP
bound in the catalytic pocket [32]. Bacterial utilization of
extracellular nucleotides is usually by dephosphorylation
followed by uptake of the nucleoside (in this case
adenosine) and inorganic phosphate [33]. Although we
began studying α,β-methylene-ADP and zinc as inhibitors
of the host cell enzyme, CD73, a side effect (or side
benefit) of these compounds may be inhibition of bacterial
5′-nucleotidase activity as well, an effect that is able to
block the nutritional benefits that E. coli bacteria derive
from extracellular AMP (Fig. 6).
Discussion
We became interested in ecto-5′-nucleotidase (CD73)
because of its likely role in the generation of adenosine
from adenine nucleotides released during EPEC infection.
This host enzyme has not received a great deal of scrutiny
in the context of microbial pathogenesis, and when it was
studied its role was felt to be in the setting of a
polymorphonuclear neutrophil (PMN) response, since acti-
vated PMNs release 5′-AMP during migration into an
infected area [4, 34]. EPEC behaves clinically as a
noninvasive pathogen and does not trigger an influx of
fecal leukocytes, but nevertheless triggers ATP release from
the host. Therefore our results suggest that ecto-5′-nucleo-
tidase plays a role in the response to a broader range of
pathogens, including noninvasive enteric pathogens, than
was previously thought.
One important finding of our study is that EPEC
infection triggers a release of ecto-5′-nucleotidase from a
cell-bound to a soluble, free form (Figs. 2 and 3). The
significance of this finding is not clear at present but there
are several possibilities to be considered. First, studies by
other investigators have shown that cleavage of ecto-5′-
nucleotidase from its GPI lipid anchor increases its activity
significantly via an increase in the Vmax [27]. This could
result in an increase in the activity of 5′-nucleotidase
present in an EPEC-infected portion of the intestine, which
could be an advantage to EPEC (see Fig. 6 and additional
discussion below). The observed increase in transcription of
ecto-5′-nucleotidase in response to EPEC infection (Fig. 3f
and Table 1), if accompanied by a similar increase in
protein synthesis and surface expression of the enzyme,
would replace ecto-5′-nucleotidase lost due to cleavage of
the lipid anchor and also contribute to an increase in total
activity. Third, release of nucleotidase from its lipid anchor
would change its distribution from a mucosal location to a
soluble form in the intestinal lumen, where it could possibly
be more accessible to substrate. This could be important in
the human or animal EPEC infection because expression of
ecto-5′-nucleotidase is highest in the intestinal crypts [35],
whereas EPEC adheres to villus tips as well as crypts. Last,
after many days of infection the mucosa could be stripped
of ecto-5′-nucleotidase activity, leading to malabsorption of
nucleotides in the diet. Indeed, malabsorption of electro-
lytes has been demonstrated after 7 days of infection in a
rabbit model of EPEC infection [36]. In addition to ecto-5′-
nucleotidase, several other important digestive enzymes
have GPI lipid anchors, including alkaline phosphatase and
aminopeptidase N (CD13) and these also could be liberated
by EPEC-induced activation of PI-PLC. Another GPI-
linked protein of interest in the intestinal tract is decay-
accelerating factor (CD55), the cellular receptor for
adhesion by diffuse adherent E. coli [37, 38] and which
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vacuoles.
Several virulent pathogens have been found to secrete
their own microbial ATPases or nucleotidases into the
extracellular medium, including Entamoeba histolytica
[39], Trichinella spiralis [40], and Vibrio cholerae [41].
Researchers have speculated that secreted microbial nucle-
otidases may serve in protection against killing by host
immune cells, acquisition of nutrients from the host, or
dampening of host immune responses. EPEC does not
appear to secrete nucleotidase activity under any conditions
we have encountered, but may achieve the same goal by
triggering the release of 5′-nucleotidase from the host cell.
Ecto-5′-nucleotidase acts on nucleoside monophos-
phates, with 5′-AMP as the preferred substrate, and is
inactive toward ATP. Therefore, the generation of AMP
from ATP requires another enzyme or enzymes. CD39, or
ectonucleoside triphosphate diphosphohydrolase, is the
major enzyme responsible for this conversion in the
cardiovascular system and probably in the gastrointestinal
tract as well [42, 43]. CD39 is also deserving of further
study in the context of microbial pathogenesis.
One surprising finding of our study was that the espF
EPEC mutant was not attenuated but in fact better than the
wild-type EPEC in release of ecto-5′-nucleotidase (Fig. 3a).
Although this mutant is defective in host cell killing, its
phenotype has been instructive in many ways. For example,
the ability of the espF mutant to trigger a robust ATP
release led to us the discovery of a new pathway for ATP
release from the host cell; this “second pathway” is not
dependent on cell death but is dependent on the cystic
fibrosis transmembrane regulator (CFTR) for ATP efflux
[19]. The competence of the espF mutant in release of ATP
and of ecto-5′-nucleotidase from the host cell may help
explain why this mutant is only modestly attenuated
compared to wild-type in some animal models of EPEC
infection, such as Citrobacter rodentium in mice [44]. On
the other hand, the sepZ/espZ mutant is attenuated in its
ability to trigger ecto-5′-nucleotidase release (Fig. 3f),
showing that type III secretion is necessary for PI-PLC
activation and release of the enzyme from its lipid anchor.
The role of ecto-5′-nucleotidase in triggering EPEC-
induced fluid secretion is highlighted in the Ussing
chamber studies shown in Fig. 5. Even after AMP has
induced a chloride secretory response, addition of the
nucleotidase inhibitor α,β-methylene-ADP is able to
reverse the short-circuit current in a manner similar to that
of an adenosine receptor antagonist, theophylline (compare
Fig. 5a and c). Tracings such as those in Fig. 5 seem to
indicate that to sustain a secretory response there must be
on ongoing production of adenosine from AMP. In other
words, there seems to be a “sink” for depletion of adenosine
from the extracellular medium, either by cellular reuptake or
by adenosine deaminase. The rapid turnover of adenosine
implied in these experiments suggested that inhibitors of
ecto-5′-nucleotidase might be able to block EPEC-induced
fluid secretion in animal models of infection.
In discussions of zinc on ecto-5′-nucleotidase it is
worthwhile to note that zinc supplements have been shown
to reduce the duration and severity of watery diarrhea in
children in developing countries around the world [45–48].
In most of these trials the microbial etiology of the diarrhea
was not carefully investigated, so it is unknown if zinc is
particularly efficacious in diarrhea due to certain pathogens,
such as EPEC, or if it beneficial “across the board” for
multiple agents. Likewise, the mechanism by which zinc
exerts its beneficial effects has not been carefully studied in
the field trials. In earlier reports it was assumed that zinc
was acting by correcting a zinc deficiency, but this
assumption has been called into question by the finding
that zinc supplements have a beneficial effect on diarrhea
even in children with normal serum zinc levels at the outset
[49]. Kelleher et al. showed that zinc provided some added
benefit beyond a probiotic (Lactobacillus rhamnosus)i n
rhesus monkeys infected with the human EPEC strain
E2348/69; the monkeys studied were not zinc deficient
[50]. Inhibition of ecto-5′-nucleotidase or K
+ channels [51]
by zinc could slow diarrhea but this should be considered a
pharmacological effect of the mineral rather than repletion of
a deficiency. Inhibition of 5′-nucleotidase also blocks the
growth-enhancing effects of AMP on EPEC bacteria (Fig. 6);
since this is a direct effect on bacterial cells this action of
zinc would not depend on the nutritional status of the host.
The effects of zinc on EPEC infection and on diarrheal
diseases in non-zinc-deficient children deserve further study.
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